MedTrace Logo

CTS2190 Phase I /II Clinical Study in Patients

NCT06224387 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2024-08-23

No results posted yet for this study

Summary

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.

Conditions

Interventions

DRUG

CTS2190 capsules

4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.

Sponsors & Collaborators

  • CytosinLab Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wu H P, Docotor · CytosinLab Therapeutics Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-26
Primary Completion
2025-07-31
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06224387 on ClinicalTrials.gov